Drug Safety

      RT @drdavidliew: DVT/PE has been the sticking point for baricitinib in RA.

      DVT/PE risk in integrated safety analysis &g

      David Liew drdavidliew

      5 years 1 month ago
      DVT/PE has been the sticking point for baricitinib in RA. DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either. Every drug has pros/cons; it's how we manage risk that counts... #ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ
      Spondyloarthritis at ACR 2020: Dr. Lianne Gensler
      5 years 1 month ago

      San Francisco-based rheumatologist Dr. Lianne Gensler examines a wide range of spondyloarthritis topics at ACR 2020, including how to join up with others interested in spondyloarthritis; enthesitis; the utility of MRI for the diagnosis for axSpA; novel treatments; and the impact of drugs on disease modification.

      RT @RichardPAConway: Dr Choi et al case control study of methotrexate in RA. No increased risk of NAFLD seen. Increased

      Richard Conway RichardPAConway

      5 years 1 month ago
      Dr Choi et al case control study of methotrexate in RA. No increased risk of NAFLD seen. Increased trigs and BMI associated NAFLD @rheumnow #ACR20 Abstr#0181 https://t.co/WLPuf6Ga1D
      RT @ejdein1: Dr. Izuka talks about drug rxn with TMP-STX in SLE, particularly in anti-Sm at #ACR20 press conference. @Ho

      Eric Dein ejdein1

      5 years 1 month ago
      Dr. Izuka talks about drug rxn with TMP-STX in SLE, particularly in anti-Sm at #ACR20 press conference. @HopkinsRheum avoids Bactrim in SLE due to flares. Whats your practice for PJP PPx in SLE? @RheumNow
      RT @Janetbirdope: What do you do with pharmacist drug alert for antimalarial cardiac safety &/or drug interactions @

      Janet Pope Janetbirdope

      5 years 1 month ago
      What do you do with pharmacist drug alert for antimalarial cardiac safety &/or drug interactions @RheumNow #ACR2020 @CRASCRRheum
      RT @rheum_cat: @JYazdanyMD @UWRheum @r_burmester Black, et al - cont'd

      277 atypical femur fx events

      Risk increased w l

      Rheum Cat rheum_cat

      5 years 1 month ago
      @JYazdanyMD @UWRheum @r_burmester Black, et al - cont'd 277 atypical femur fx events Risk increased w longer duration of bisphosphonate use Risk decreased after bisphosphonate discontinuation Asians had a higher risk than Whites. #ACR20 #ACRambassador
      RT @KDAO2011: 4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6,
      cirrhosis NNH 1000
      5.LoDoCo2: colchicine p

      k dao KDAO2011

      5 years 1 month ago
      4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6, cirrhosis NNH 1000 5.LoDoCo2: colchicine prevents MACE: NNT 36 6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ: NNH 600
      RT @DrMiniDey: Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity

      Mrinalini Dey DrMiniDey

      5 years 1 month ago
      Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity to learn about side-effects" of a drug we commonly use. Low-dose MTX assoc. with small-mod. elevated risk of transaminitis, infection, anaemia & skin cancer. #ACR20 @RheumNow https://t.co/hNS600Pndr
      RT @ejdein1: How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdany

      Eric Dein ejdein1

      5 years 1 month ago
      How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdanyMD Year-in-Review #ACR20 @rheumnow
      RT @drpnash: Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Re

      Peter Nash drpnash

      5 years 1 month ago
      Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need
      RT @drpnash: Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA

      Peter Nash drpnash

      5 years 1 month ago
      Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response
      RT @drpnash: Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat

      Peter Nash drpnash

      5 years 1 month ago
      Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat
      RT @RichardPAConway: #ACR20 year in review @JYazdanyMD CIRT trial showing that MTX pneumonitis occurs but is very (very)

      Richard Conway RichardPAConway

      5 years 1 month ago
      #ACR20 year in review @JYazdanyMD CIRT trial showing that MTX pneumonitis occurs but is very (very) rare. @RheumNow @jeffsparks @DanielHSolomon https://t.co/UbD4mhHBzq
      infx.pneumonia.jpg
      TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months
      5 years 1 month ago
      The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

      Catch up on Conference Podcasts

      ×